Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Investing.com - Leerink Partners has raised its price target on Amarin Corporation (NASDAQ:AMRN) to $12.00 from $10.00 while maintaining a Market Perform rating following the company’s third-quarter 2025 results. The stock, currently trading at $16.81, appears undervalued according to InvestingPro’s Fair Value model, despite experiencing a significant 13.6% decline over the past week.
Amarin reported total net revenue of $49.7 million for the quarter, representing a 17% year-over-year increase. This growth was primarily driven by stronger U.S. performance, where revenue reached $40.9 million, up 34% from the same period last year due to improved net pricing and volume gains from regained pharmacy benefit manager exclusivity.
Operating expenses decreased significantly, falling 20% year-over-year to $33.3 million, with selling, general and administrative expenses down 47% following the company’s restructuring efforts. Management reiterated its goal of achieving positive free cash flow in 2026 and highlighted Amarin’s debt-free balance sheet with approximately $290 million in cash. InvestingPro data confirms this strong liquidity position with a healthy current ratio of 3.26, indicating liquid assets substantially exceed short-term obligations. While not profitable over the last twelve months, analysts tracked by InvestingPro expect the company to turn profitable this year.
European revenue remained essentially flat at $4.1 million as Amarin continues its transition to a partnered model with Recordati, while Rest of World revenue declined to $3.6 million due to normal quarterly variability in partnership supply dynamics.
Leerink Partners noted that a recent FDA labeling update for fenofibrate could represent a tailwind for Vascepa, as the update revised fenofibrate’s indication to reflect a lack of cardiovascular benefit and highlighted safety concerns when co-administered with statins.
In other recent news, Amarin Corporation reported its third-quarter earnings for 2025, highlighting a 17% increase in total net revenue year-over-year, reaching $49.7 million. Despite facing an operating loss of $11.1 million, the company made significant improvements in its operating margin. These financial results indicate ongoing investor confidence in Amarin’s restructuring efforts. The earnings report did not include any updates on mergers or acquisitions. Analyst firms have not recently issued any upgrades or downgrades for the company. There were no additional major announcements or developments from Amarin. These recent developments reflect Amarin’s current financial and operational status.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.